ANL
Adlai Nortye Ltd.
NASDAQ · Healthcare · Biotechnology · KY
$10.28
+0.78%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +49.8%
- EBITDA
- +71.4%
- EPS
- +74.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- +32.1%
- EBIT
- +32.6%
- Net income
- +31.5%
- EPS
- +31.9%
- Free cash flow
- +35.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026